When considered purely based on the neuropathological diagnosis of either non-AD controls versus AD, levels of AT-8 phospho-tau were elevated in AD cases, both in GM (13.24 ± 3.3 fold cf. non-AD, p < 0.001, Fig. 1a.i + b.i) and WM (9 ± 2.6 fold cf. non-AD, p < 0.001, Fig. 1a.i + b.i). This evidence concerns the gene MAPT and Alzheimer disease.